Our data bring the first clinical clue that NCL could be not only an useful biomarker to better stratify breast cancer patients when combined with the current gold-standard biomarkers, but also a promising target for NCL-overexpressing breast tumours to improve breast cancer management. The gene discussed is NUCLEOLIN; the disease is breast neoplasm.